Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19146


Purpose:

This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.


Study summary:

The protocol requires all participants to be treated with Avonex and in addition patients will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated neurological and clinical examinations are performed with laboratory tests to determine any possible adverse drug effects. The scaled neurologic examinations (EDSS and MSFC) and brain MRI's are done at regular intervals to evaluate possible treatment effects.


Criteria:

Inclusion Criteria: Relapsing-remitting multiple sclerosis - Exclusion Criteria: Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -


NCT ID:

NCT00217295


Primary Contact:

Principal Investigator
Jeffrey I Greenstein, MD
MSI

Jeffrey I Greenstein, MD
Phone: 215-985-2245


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19146
United States

Jeffrey I Greenstein, MD
Phone: 215-985-2245

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.